Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

"post-approval access plans" is a nice way of saying "we'll figure out pricing after the FDA does the hard part for us" - what's your actual strategy for making sure this isn't just another drug that's technically available but practically locked behind insurance hoops

so is this another $2k/month or are we actually making it accessible

聖地で撮った写真を見返すとまた涙が出る

B-17... natures prep.

what’s the uninsured copay strategy vs generic daily PrEP

curious how you’re pricing it - tiered by risk or flat?

patient assistance program or just a copay card

partnering with community clinics or big chains for distribution?

curious how this compares to the daily pill for dosing

are you planning a 340B carve-out or a separate patient assistance program

hope this doesn't take another 20 years to actually become available